- Home
- LH vs CBOE Comparison
LH vs CBOE Comparison
Compare LH & CBOE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LH | CBOE |
|---|---|---|
| Founded | 1971 | 1973 |
| Country | United States | United States |
| Employees | 70000 | N/A |
| Industry | Medical Specialities | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.9B | 25.6B |
| IPO Year | 2005 | 2010 |
Fundamental Metrics
Financial Performance| Metric | LH | CBOE |
|---|---|---|
| Price | $320.49 | $285.02 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 9 |
| Target Price | ★ $311.33 | $289.44 |
| AVG Volume (30 Days) | 762.6K | ★ 1.0M |
| Earning Date | 04-30-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.12% | 0.94% |
| EPS Growth | 18.33 | ★ 44.52 |
| EPS | 6.99 | ★ 7.01 |
| Revenue | ★ $13,951,700,000.00 | $2,229,100,000.00 |
| Revenue This Year | $8.26 | N/A |
| Revenue Next Year | $4.81 | $3.54 |
| P/E Ratio | $45.87 | ★ $40.93 |
| Revenue Growth | 7.25 | ★ 239.31 |
| 52 Week Low | $244.52 | $227.15 |
| 52 Week High | $321.34 | $371.18 |
Technical Indicators
Market Signals| Indicator | LH | CBOE |
|---|---|---|
| Relative Strength Index (RSI) | 72.13 | 49.56 |
| Support Level | $251.37 | $274.41 |
| Resistance Level | N/A | $305.98 |
| Average True Range (ATR) | 8.49 | 10.71 |
| MACD | 1.12 | -1.04 |
| Stochastic Oscillator | 98.54 | 20.73 |
Price Performance
Historical ComparisonAbout LH Laboratory Corporation of America Holdings
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.
About CBOE Cboe Global Markets Inc.
Founded in 1973, Cboe controls the largest option exchange in the US, which provides around 60% of the firm's revenue. The company is best known for its proprietary S&P 500 and VIX index options, which it offers through an exclusive contract with S&P Global. The firm moved into US and European equities through the $3.4 billion acquisition of BATS in 2017. Cboe has continued to look to expand internationally, using acquisitions to build a presence in both Canada and Australia.